New combo therapy aims to shrink tumors before liver cancer surgery
NCT ID NCT07239245
Summary
This study is testing a three-part treatment given before surgery for patients with liver cancer that has a high chance of coming back. Doctors combine a procedure that delivers chemotherapy directly to the tumor (TACE) with two immunotherapy drugs (atezolizumab and bevacizumab). The goal is to see if this approach can kill more cancer cells before surgery, potentially leading to better long-term outcomes by reducing the risk of the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.